Coenzyme Q10 Supplementation and Development of Preeclampsia

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00300937
• Date of registration: 08/03/2006
• Primary sponsor: Teran, Enrique, MD, PhD
• Public title: Coenzyme Q10 Supplementation and Development of Preeclampsia
• Scientific title: Coenzyme Q10 Supplementation in Pregnant Women as Strategy to Reduce Maternal Morbidity Due to Preeclampsia
• Date of first enrolment: July 2004
• Target sample size: 235
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00300937
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Countries of recruitment

Ecuador

Contacts

• Name: Enrique Teran, MD, PhD
• Affiliation: Biomedical Center - Central University of Ecuador

Key inclusion & exclusion criteria

Inclusion Criteria:

- Primigravidae

- Younger than 25 years old

- No history of disease related to cardiovascular, endocrine, metabolic or reproductive
systems

- To be recruited before than week 20 of gestation

- To sign the Informed Consent form

Exclusion Criteria:

- Voluntary withdrawal

- Poor compliance of visit/treatment



Age minimum: 14 Years
Age maximum: 25 Years
Gender: Female

Health Condition(s) or Problem(s) studied

Preeclampsia

Intervention(s)

Dietary Supplement: Coenzyme Q10

Primary Outcome(s)

Preeclampsia rate in both groups [Time Frame: Delivery]

Secondary Outcome(s)

Newborns weight [Time Frame: Delivery]

Secondary ID(s)

PFN-03-053

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Central University, Ecuador

Ecuadorian Foundation for Science and Technology - FUNDACYT

Jarrow Formulas Inc